Marginal Zone Lymphoma: Relapsed/Refractory
The term “relapsed” refers to disease that reappears or grows again after a period of remission.
The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.
Although many patients go into a remission that lasts for years after their initial treatment, the disease can return.
For those who need treatment, the same therapies used for newly diagnosed patients can often be used in patients with relapsed/refractory MZL.
Treatment for relapsed/refractory MZL is based on a patient’s age, overall health, symptoms, and the duration of remission from the last treatment they received. Treatment options commonly used for relapsed/refractory MZL include:
- R² – rituximab and lenalidomide (Rituxan and Revlimid)
- Rituximab (Rituxan)
- Ibrutinib (Imbruvica)
- Umbralisib (UKONIQ)
- Zanubrutinib (BRUKINSA)
To learn about treatments under investigation for marginal zone lymphoma, download the Marginal Zone Lymphoma Fact Sheet.
Download the Clinical Trials Fact Sheet.